BioSpace News Archive

AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and enrolling patients

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α- and β-thalassemia.

Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, announced the oral presentation of updated data from its French Phase 1b/2 clinical trial at the 25th European Hematology Association Annual Meeting.

Centene Corporation announced on June 12, 2020 its updated 2020 financial guidance. Total revenues are expected to be $109.5 billion to $111.9 billion, and diluted earnings per share are expected to be $3.06 to $3.20.

The global rheumatoid arthritis drugs market was valued at US$ 19597.4 Mn in 2016.

Transparency Market Research has published a new report titled, “Anticoagulant Reversal Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

The global viral vector and plasmid DNA testing services market is estimated to be influenced by the increased innovation and spending in research and development activities relating to the field.

The growth of the global sarcoma biopsy market relies on advancements in cancer therapies.

Methicillin Resistant Staphylococcus aureus is the most prevalent multi-drug resistant bacteria and a growing threat to health.

Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for absolute neutrophil count as primary endpoint